This Article Full Text Full Text (PDF) All Versions of this Article: 39/5/1406    most recent STROKEAHA.107.506832v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lip, G. Y.H. Search for Related Content PubMed PubMed Citation Articles by Lip, G. Y.H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID WARFARIN Medline Plus Health Information Atrial Fibrillation Blood Thinners Stroke Related Collections Other Stroke Treatment - Medical Related Article

(Stroke. 2008;39:1406.)
© 2008 American Heart Association, Inc.

Editorials

The Balance Between Stroke Prevention and Bleeding Risk in Atrial Fibrillation

A Delicate Balance Revisited

Gregory Y.H. Lip, MD

From the University Department of Medicine, City Hospital, Birmingham, England, UK.

Correspondence to Prof. G.Y.H. Lip, University Department of Medicine, City Hospital, Birmingham, England, UK B18 7QH. E-mail g.y.h.lip@bham.ac.uk

Key Words: atrial fibrillation • bleeding anticoagulation • stroke • thromboembolism

An extract of the first 250 words of the full text is provided, because this article has no abstract.

See related article, pages 1482–1486.

Although atrial fibrillation (AF) is well recognized to confer a risk of stroke, this risk is not homogeneous. Oral anticoagulation (OAC) with warfarin is highly beneficial, but such therapy is inconvenient and carries a risk of bleeding. Thus, stroke risk stratification schemes have been devised to identify "high risk" AF patients for whom the absolute benefits of OAC exceed its risks.

In general, present treatment guidelines recommend OAC for those classed at high risk of stroke, and aspirin for those at "low risk." In those at "moderate risk," either OAC or aspirin is recommended. There are many ways of classifying stroke risk, and in a recent comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular AF, the Stroke Risk in Atrial Fibrillation Working Group¹ identified 7 schemes that were based directly on event-rate analyses (largely been identified from non-OAC arms of clinical trials, and occasionally from cohort studies), whereas 5 resulted from expert panel consensus. The most frequently included features were prior stroke/TIA (in 100% of schemes), patient age, hypertension and diabetes mellitus.

Of the various published schema, the CHADS2 score is probably the most popular, which is well validated and easy to use, where 1 point is given for Congestive heart failure, Hypertension, Age >75 and Diabetes, whereas 2 points are given for Stroke or transient ischemic attack (TIA).²

Based on published test study cohorts, the absolute stroke rates for the different stroke risk schema varied rather widely, and . . . [Full Text of this Article]

Related Article:

Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)

Jeff S. Healey, Robert G. Hart, Janice Pogue, Marc A. Pfeffer, Stefan H. Hohnloser, Raffaele De Caterina, Greg Flaker, Salim Yusuf, and Stuart J. Connolly
Stroke 2008 39: 1482-1486. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				D. Poli, E. Antonucci, E. Grifoni, R. Abbate, G. F. Gensini, and D. Prisco Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J. Am. Coll. Cardiol., September 8, 2009; 54(11): 999 - 1002. [Abstract] [Full Text] [PDF]